Revenue Breakdown — Amgen Inc. (AMGN)

Fiscal Year	Repatha	EVENITY	Prolia	TEPEZZA	KRYSTEXXA	UPLIZNA	TAVNEOS	Ultra-Rare products	TEZSPIRE	Otezla	Enbrel	AMJEVITA/AMGEVITA	BLINCYTO	Vectibix	KYPROLIS	LUMAKRAS/LUMYKRAS	XGEVA	Nplate	IMDELLTRA	MVASI	EPOGEN	Aranesp	Parsabiv	Neulasta	NEUPOGEN	Sensipar/Mimpara	Other products	Other revenues
FY2021	$1.12B	$530.0M	$3.25B	—	—	—	—	—	—	$2.25B	$4.47B	—	—	—	$1.11B	—	$2.02B	$1.03B	—	—	—	$1.48B	—	$1.73B	—	—	$5.32B	$1.68B
FY2022	$1.30B	$787.0M	$3.63B	—	—	—	—	—	—	$2.29B	$4.12B	—	—	—	$1.25B	—	$2.01B	$1.31B	—	—	—	$1.42B	—	$1.13B	—	—	$5.57B	$1.52B
FY2023	$1.64B	$1.16B	$4.05B	$448.0M	$272.0M	$65.0M	$134.0M	$164.0M	$567.0M	$2.19B	$3.70B	$626.0M	$861.0M	$984.0M	$1.40B	$280.0M	$2.11B	$1.48B	—	$800.0M	$226.0M	$1.36B	$362.0M	$848.0M	—	—	$1.19B	$1.28B
FY2024	$2.22B	$1.56B	$4.37B	$1.85B	$1.19B	$379.0M	$283.0M	$758.0M	$972.0M	$2.13B	$3.32B	$761.0M	$1.22B	$1.05B	$1.50B	$350.0M	$2.23B	$1.46B	$115.0M	$727.0M	$125.0M	$1.34B	$356.0M	$431.0M	—	—	$1.35B	$1.40B
FY2025	$3.02B	$2.10B	$4.41B	$1.90B	$1.34B	—	—	—	$1.48B	$2.27B	$2.23B	—	$1.56B	$1.18B	$1.41B	—	$2.08B	$1.52B	—	—	—	$1.39B	—	—	—	—	$7.26B	$1.60B